Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for XNCR

Stock NameXencor Inc
TickerXNCR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS98401F1057

Show aggregate XNCR holdings

News associated with XNCR

Barclays Initiates Coverage on Xencor (NASDAQ:XNCR)
Research analysts at Barclays began coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set an “underweight” rating and a $6.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential downside of 40.18% from the stock’s previous close. A number […] - 2025-09-19 02:46:44
Xencor (NASDAQ:XNCR) Shares Gap Down After Analyst Downgrade
Xencor, Inc. (NASDAQ:XNCR – Get Free Report)’s share price gapped down prior to trading on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The stock had previously closed at $8.55, but opened at $8.00. Bank of America now has a $12.00 price target on the stock, down […] - 2025-09-05 02:15:52
Xencor (NASDAQ:XNCR) vs. Enliven Therapeutics (NASDAQ:ELVN) Critical Comparison
Xencor (NASDAQ:XNCR – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk. Earnings & Valuation This table compares Xencor and […] - 2025-08-27 04:54:48
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target […] - 2025-08-22 02:42:55
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Alps Advisors Inc.
Alps Advisors Inc. lowered its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 9.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,459 shares of the biopharmaceutical company’s stock after selling 5,126 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:25:57
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by New York State Teachers Retirement System
New York State Teachers Retirement System boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,326 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during […] - 2025-07-11 05:14:58
Xencor (NASDAQ:XNCR) Trading Down 5.7% Following Insider Selling
Xencor, Inc. (NASDAQ:XNCR – Get Free Report) shares fell 5.7% during trading on Tuesday following insider selling activity. The stock traded as low as $8.67 and last traded at $8.53. 67,899 shares were traded during mid-day trading, a decline of 90% from the average session volume of 664,926 shares. The stock had previously closed at […] - 2025-06-19 02:13:09
Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Average Target Price from Analysts
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy […] - 2025-06-11 04:40:45
California State Teachers Retirement System Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)
California State Teachers Retirement System increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,130 shares of the biopharmaceutical company’s stock after buying an additional 6,376 shares during the period. […] - 2025-06-10 04:22:46
53,397 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Public Employees Retirement System of Ohio
Public Employees Retirement System of Ohio acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 53,397 shares of the biopharmaceutical company’s stock, valued at approximately $1,227,000. Other large investors have also modified their holdings of the company. Sterling Capital Management LLC boosted […] - 2025-06-03 05:30:52
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 23.4% in the 4th quarter, HoldingsChannel reports. The fund owned 40,355 shares of the biopharmaceutical company’s stock after purchasing an additional 7,650 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Xencor were […] - 2025-05-27 04:46:48
Head to Head Analysis: Xencor (NASDAQ:XNCR) versus Dermata Therapeutics (NASDAQ:DRMA)
Xencor (NASDAQ:XNCR – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations. Valuation and Earnings This table compares Xencor and […] - 2025-05-21 03:14:50
Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)
Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […] - 2025-05-13 02:04:46
Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Tower Research Capital LLC TRC
Tower Research Capital LLC TRC boosted its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 132.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,865 shares of the biopharmaceutical company’s stock after purchasing an additional 4,482 shares during the quarter. Tower Research […] - 2025-05-06 05:17:02
Dimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)
Dimensional Fund Advisors LP grew its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,501,532 shares of the biopharmaceutical company’s stock after purchasing an additional 102,297 shares during the period. Dimensional Fund […] - 2025-05-05 05:21:10
10,408 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Bank of Montreal Can
Bank of Montreal Can purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $239,000. Several other institutional investors have also added to or reduced their stakes in XNCR. Finepoint Capital LP […] - 2025-04-25 04:36:48
William Blair Begins Coverage on Xencor (NASDAQ:XNCR)
Research analysts at William Blair initiated coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. Wells Fargo & Company dropped their […] - 2025-04-23 02:11:01
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by Legal & General Group Plc
Legal & General Group Plc lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,514 shares of the biopharmaceutical company’s stock after acquiring an additional 20,141 shares during the quarter. […] - 2025-04-22 04:47:07
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Russell Investments Group Ltd.
Russell Investments Group Ltd. lessened its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 216,291 shares of the biopharmaceutical company’s stock after selling 16,734 shares during the quarter. Russell Investments […] - 2025-04-15 05:33:08
Pictet Asset Management Holding SA Invests $247,000 in Xencor, Inc. (NASDAQ:XNCR)
Pictet Asset Management Holding SA acquired a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 10,740 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes […] - 2025-04-11 05:58:59
Norges Bank Makes New Investment in Xencor, Inc. (NASDAQ:XNCR)
Norges Bank acquired a new stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 147,823 shares of the biopharmaceutical company’s stock, valued at approximately $3,397,000. A number of other institutional investors and hedge funds have also recently […] - 2025-04-11 05:12:49
Xencor, Inc. (NASDAQ:XNCR) Stock Position Lifted by Vanguard Group Inc.
Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,017,366 shares of the biopharmaceutical company’s stock after acquiring an additional 418,040 shares during the period. Vanguard Group Inc. owned 0.11% of Xencor worth $184,239,000 as of its […] - 2025-04-07 05:06:58
Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Prudential Financial Inc.
Prudential Financial Inc. increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,715 shares of the biopharmaceutical company’s stock after acquiring an additional 6,810 shares during […] - 2025-04-06 05:30:53
Teacher Retirement System of Texas Buys 3,250 Shares of Xencor, Inc. (NASDAQ:XNCR)
Teacher Retirement System of Texas boosted its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,645 shares of the biopharmaceutical company’s stock after purchasing an additional 3,250 shares during […] - 2025-04-01 04:40:45
Thrivent Financial for Lutherans Has $2.82 Million Stock Position in Xencor, Inc. (NASDAQ:XNCR)
Thrivent Financial for Lutherans grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,897 shares of the biopharmaceutical company’s stock after buying an additional 6,528 shares during the quarter. Thrivent Financial […] - 2025-03-28 06:18:47
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-03-25 04:26:50
Analysts Forecast 25% Upside For VB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-21 08:40:03
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by US Bancorp DE
US Bancorp DE cut its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 75.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,532 shares of the biopharmaceutical company’s stock after selling 7,843 shares during the period. US Bancorp DE’s holdings in Xencor were […] - 2025-03-19 05:10:48
Wells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00
Xencor (NASDAQ:XNCR – Free Report) had its target price lowered by Wells Fargo & Company from $37.00 to $33.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. […] - 2025-03-03 04:21:01
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-02-28 06:35:19

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc XNCR holdings

DateNumber of XNCR Shares HeldBase Market Value of XNCR SharesLocal Market Value of XNCR SharesChange in XNCR Shares HeldChange in XNCR Base ValueCurrent Price per XNCR Share HeldPrevious Price per XNCR Share Held
2025-09-30 (Tuesday)5,824USD 68,316USD 68,316
2025-09-29 (Monday)5,788USD 66,851USD 66,851
2025-09-26 (Friday)5,788USD 66,967USD 66,967
2025-09-25 (Thursday)5,788USD 59,790XNCR holding decreased by -810USD 59,7900USD -810 USD 10.33 USD 10.4699
2025-09-24 (Wednesday)5,788USD 60,600USD 60,600
2025-09-17 (Wednesday)5,752USD 53,206XNCR holding increased by 3624USD 53,2060USD 3,624 USD 9.25 USD 8.61996
2025-09-16 (Tuesday)5,752USD 49,582USD 49,582
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of XNCR by Blackrock for IE00B3VWM098

Show aggregate share trades of XNCR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-18 7.440* 13.79 Profit of 248 on sale
2025-07-31BUY54 8.320* 13.86
2025-06-30SELL-36 7.860* 14.52 Profit of 523 on sale
2025-06-25SELL-18 8.560* 14.65 Profit of 264 on sale
2025-06-20SELL-36 8.540* 14.78 Profit of 532 on sale
2025-05-23BUY18 7.570* 15.79
2025-05-19SELL-18 8.060* 16.06 Profit of 289 on sale
2025-05-15SELL-54 8.200* 16.20 Profit of 875 on sale
2025-05-12SELL-18 8.770* 16.41 Profit of 295 on sale
2025-05-09SELL-18 8.330* 16.48 Profit of 297 on sale
2025-04-30SELL-18 11.020* 16.93 Profit of 305 on sale
2025-04-24SELL-36 10.840* 17.18 Profit of 619 on sale
2025-04-17SELL-18 9.700* 17.54 Profit of 316 on sale
2025-04-15SELL-54 9.540* 17.72 Profit of 957 on sale
2025-04-14SELL-54 8.940* 17.81 Profit of 962 on sale
2025-04-09SELL-72 8.810* 18.13 Profit of 1,305 on sale
2025-04-07SELL-126 8.370* 18.36 Profit of 2,313 on sale
2025-04-04SELL-180 8.690* 18.47 Profit of 3,325 on sale
2025-03-31BUY18 10.640* 18.78
2025-03-19SELL-36 13.140* 19.47 Profit of 701 on sale
2025-03-14SELL-108 12.760* 19.75 Profit of 2,133 on sale
2025-03-13SELL-36 12.870* 19.84 Profit of 714 on sale
2025-03-12SELL-612 13.130* 19.94 Profit of 12,203 on sale
2025-03-07SELL-36 13.870* 20.22 Profit of 728 on sale
2025-03-06SELL-54 13.850* 20.32 Profit of 1,097 on sale
2025-03-03SELL-18 14.460* 20.61 Profit of 371 on sale
2025-02-28SELL-108 15.360* 20.69 Profit of 2,235 on sale
2025-02-26SELL-18 14.380* 20.90 Profit of 376 on sale
2025-02-25SELL-54 14.450* 21.00 Profit of 1,134 on sale
2025-02-18BUY90 16.220* 21.59
2025-02-13BUY18 16.290* 21.90
2025-02-12BUY18 16.220* 22.02
2025-02-11BUY54 16.130* 22.14
2025-02-06BUY162 17.250* 22.48
2025-01-27BUY18 19.230* 23.37
2024-12-30BUY90 23.710* 23.55
2024-12-06BUY72 25.340* 23.37
2024-12-05BUY18 25.320* 23.31
2024-12-04BUY90 26.200* 23.20
2024-11-29BUY90 25.600* 22.83
2024-11-27BUY72 25.620* 22.58
2024-11-26BUY18 25.300* 22.46
2024-11-25SELL-4,737 26.060* 22.29 Profit of 105,574 on sale
2024-11-21BUY160 24.100* 22.05
2024-11-20BUY96 23.720* 21.96
2024-11-18BUY384 23.190* 21.77
2024-11-12BUY256 23.710* 21.64
2024-11-08BUY160 23.620* 21.50
2024-11-07BUY480 23.180* 21.37
2024-11-06BUY64 22.680* 21.27
2024-10-31BUY32 21.010* 21.23
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of XNCR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19441,0430699,16963.1%
2025-09-18355,3200679,37252.3%
2025-09-17293,2590484,81960.5%
2025-09-16102,8170219,24846.9%
2025-09-15305,8570441,74769.2%
2025-09-12139,1840241,19757.7%
2025-09-11116,0850466,59524.9%
2025-09-10131,9410251,55052.5%
2025-09-0965,6930308,39121.3%
2025-09-08129,6770214,36560.5%
2025-09-05110,5730181,05261.1%
2025-09-0469,3150426,04716.3%
2025-09-03131,0610222,78058.8%
2025-09-02113,8830274,94441.4%
2025-08-29109,9640426,34125.8%
2025-08-2890,0020140,21764.2%
2025-08-27296,4420650,72345.6%
2025-08-26144,4500345,86941.8%
2025-08-25119,73693238,93750.1%
2025-08-22195,2100362,90653.8%
2025-08-2151,99810096,81053.7%
2025-08-2035,4685162,33356.9%
2025-08-1969,0730115,30259.9%
2025-08-1878,7160116,55267.5%
2025-08-1556,5530121,85746.4%
2025-08-1483,8250189,10244.3%
2025-08-1394,7380327,89928.9%
2025-08-12139,6400379,02436.8%
2025-08-11145,5580325,98644.7%
2025-08-08139,4270278,21050.1%
2025-08-07167,69625428,18839.2%
2025-08-06117,30061197,83359.3%
2025-08-0586,4000230,65737.5%
2025-08-0479,1790198,92739.8%
2025-08-01100,4530414,16624.3%
2025-07-3194,62383234,87040.3%
2025-07-30168,9100227,32074.3%
2025-07-2971,6720104,99168.3%
2025-07-2889,9570120,69074.5%
2025-07-2578,0770136,93257.0%
2025-07-24116,7600178,38465.5%
2025-07-23179,8650277,40564.8%
2025-07-22106,6133,584223,16447.8%
2025-07-2172,4760170,10842.6%
2025-07-1872,2270112,64364.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.